Recent studies [18,40] have proposed ODC1 as a suitable therapeutic target for AD; however, it has been shown that difluoromethylornithine, an ODC1 inhibitor, requires high dosage and has toxic side effects [41,42]. This evidence concerns the gene ODC1 and Alzheimer disease.